Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Cefixime (FR-17027; Unixime; Cefiximum; Cefixima; FK-027; CL-284635) is a novel and potent third generation cephalosporin antibiotic with activity against a variety of Gram-negative bacteria, including E. coli, K. pneumoniae, and H. influenzae. Cefixime binds to penicillin-binding proteins and is stable to many penicillinases and β-lactamases. It is an effective, orally-active cephalosporin with applications in acute otitis media, respiratory tract infections, and urinary tract infections.
Targets |
β-lactam
|
---|---|
ln Vitro |
With a MIC90 value of 0.25 μg/mL, cefixime exhibits strong antibacterial activity against clinical isolates of Salmonella typhi. It also exhibits antibacterial activity against strains that are resistant to amoxicillin (HY-B0467A) and produce β-lactamase.
|
ln Vivo |
Mice challenged with FA1090 (ESC-susceptible strain) have lower bacterial burdens when cefixime (0.75–60 mg/kg) is administered orally[4].
Cefixime (50 or 150 mg/kg, oral gavage) alters the composition and diversity of the C57BL/6J mice's gut microbiota, resulting in a decrease in the microbial community's diversity and a shift toward a predominate Firmicutes phylum[5].
|
References |
|
Molecular Formula |
C16H15N5O7S2
|
---|---|
Molecular Weight |
453.45
|
Exact Mass |
453.04129
|
Elemental Analysis |
C, 42.38; H, 3.33; N, 15.44; O, 24.70; S, 14.14
|
CAS # |
79350-37-1
|
Related CAS # |
Cefixime trihydrate;125110-14-7
|
Appearance |
Off-white to slightly yellow solid powder.
|
SMILES |
O=C(C(N12)=C(C=C)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OCC(O)=O)=O)C1=O)O
|
InChi Key |
OKBVVJOGVLARMR-VINNURBNSA-N
|
InChi Code |
InChI=1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9+/t10-,14-/m1/s1
|
Chemical Name |
(6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
Synonyms |
Cefixima; FR17027; Suprax; Trihydrate, Cefixime; FK 027; FK-027; FK027; FR 17027; FR-17027;Cefixim; Cefixoral; Unixime; Cefiximum;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 90~100 mg/mL ( 198.47~220.53 mM )
Ethanol : ~1 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.51 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (5.51 mM) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2053 mL | 11.0266 mL | 22.0531 mL | |
5 mM | 0.4411 mL | 2.2053 mL | 4.4106 mL | |
10 mM | 0.2205 mL | 1.1027 mL | 2.2053 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.